EU Firsts Beckon For Alnylam & Novo; Wins For A Raft Of Others
Executive Summary
A plethora of new drugs moved closer to the EU market this week after the European Medicines Agency recommended that they should be approved.
You may also be interested in...
New CLL Treatment Paradigm Nears In EU For AbbVie
The first chemotherapy-free, first-line treatment for chronic lymphocytic leukemia where dosing can be completed in one year has received the thumbs up by the European Medicines Agency.
Novo’s Rybelsus Pill Set To Disrupt Europe’s Diabetes Market
Rybelsus, the first oral GLP-1 treatment for type 2 diabetes, will likely secure EU approval in a couple of months.
EU: PRIME Success For Givlaari At CHMP
Interaction with the European Medicines Agency on Givlaari helped Alnylam prepare a more robust application package to demonstrate the medicine’s benefits and risks.